Chris Howerton
Stock Analyst at Jefferies
(2.46)
# 2,345
Out of 4,734 analysts
75
Total ratings
43.33%
Success rate
12.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.01 | +59.68% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $27.06 | +191.94% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.98 | +102.02% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.98 | +2.52% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $20 → $22 | $0.34 | +6,295.35% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $6.75 | +10,566.67% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.25 | -77.78% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $10.27 | -2.63% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.87 | -30.26% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $7.75 | +41.94% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $29.94 | +33.62% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $39.05 | +56.21% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $91.94 | -2.10% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.36 | +175.23% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.77 | +7,018.64% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.84 | +2,290.63% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $23.78 | +177.54% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $0.55 | +5,364.48% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.67 | +230.08% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.40 | +775.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.33 | +1,554.14% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $0.94 | +2,346.81% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $17.57 | +19.52% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.77 | +3,678.99% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.06 | +5,560.38% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $55.31 | -71.07% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $36.82 | -26.67% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.19 | +12,491.82% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.01
Upside: +59.68%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $27.06
Upside: +191.94%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.98
Upside: +102.02%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.98
Upside: +2.52%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $20 → $22
Current: $0.34
Upside: +6,295.35%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $6.75
Upside: +10,566.67%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.25
Upside: -77.78%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $10.27
Upside: -2.63%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.87
Upside: -30.26%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $7.75
Upside: +41.94%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $29.94
Upside: +33.62%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $39.05
Upside: +56.21%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $91.94
Upside: -2.10%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.36
Upside: +175.23%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.77
Upside: +7,018.64%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.84
Upside: +2,290.63%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $23.78
Upside: +177.54%
Aug 24, 2021
Initiates: Buy
Price Target: $30
Current: $0.55
Upside: +5,364.48%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $6.67
Upside: +230.08%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $2.40
Upside: +775.00%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.33
Upside: +1,554.14%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $0.94
Upside: +2,346.81%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $17.57
Upside: +19.52%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.77
Upside: +3,678.99%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.06
Upside: +5,560.38%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $55.31
Upside: -71.07%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $36.82
Upside: -26.67%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.19
Upside: +12,491.82%